Astellas Stays Competitive in Hot Gut Cancer Target, Paying $130M to License Evopoint Drug
Astellas Pharma gets global rights to an Evopoint Biosciences antibody drug conjugate that targets Claudin…
Astellas Stays Competitive in Hot Gut Cancer Target, Paying $130M to License Evopoint Drug
Astellas Pharma gets global rights to an Evopoint Biosciences antibody drug conjugate that targets Claudin 18.2. Last year, Astellas’s antibody drug Vyloy became the first FDA-approved therapy for this target. The post Astellas Stays Competitive in Hot Gut Cancer Target, Paying $130M to License Evopoint Drug appeared first on MedCity News.
Your weekend reading
A list of interesting articles to checkout as you head to the weekend. How America Built the World’s Most Successful Market for Generic Drugs.Reference Pricing as a Deterrent to Entry.Will Florida Medicaid cover a hospitalization in South Dakota?Will better data rescue value-based care?The return of COVID?
4 Notable Health Tech Funding Announcements in May
Health tech companies made several major funding announcements in May. Here is a list of some of the biggest funding rounds. The post 4 Notable Health Tech Funding Announcements in May appeared first on MedCity News.
Healthcare Moves: A Monthly Summary of Hires, Exits and Layoffs
May has seen a slew of executive hires, exits and layoffs across the healthcare industry. For example, the American Medical Association and TigerConnect named new CEOs, and Google and UnitedHealth Group have seen key executives leave their roles. There were also layoffs at organizations including Devoted Health and New York-Presbyterian. The post Healthcare Moves: A…
MedCity FemFwd: Investment Trends In Women’s Health
In this episode, we’re joined by Margaret Malone, principal of Flare Capital Partners. She discusses the investment trends she’s following in the women’s health space and advice she has for startups. The post MedCity FemFwd: Investment Trends In Women’s Health appeared first on MedCity News.
At Trump’s FDA, Anti-Regulatory Approach and Cost-Cutting Put Food Safety System at Risk
The Trump administration’s anti-regulatory approach and cost-cutting moves risk unraveling a critical system of checks and balances that helps ensure the safety of the U.S. food supply, industry experts told KFF Health News. An E. coli outbreak that occurred late last year — for which the investigation was concluded in February — signals how, with…
The Performance of the Federal Independent Dispute Resolution Process through Mid-2024
The No Surprises Act, which was signed into law by President Trump during his first term and took effect in 2022, aims to protect consumers from certain surprise medical bills. The law established processes to keep the patient out of the payment negotiations between the provider and the plan. In the event of an unsuccessful…More
Allocating CBO’s Estimates of Federal Medicaid Spending Reductions and Enrollment Loss Across the States
The Congressional Budget Office’s (CBO) latest cost estimate shows that the One Big Beautiful Bill would reduce federal Medicaid spending by $723 billion, with an estimated Medicaid enrollment loss of 10.3 million people in 2034. Building on prior KFF analysis, this analysis allocates these estimated federal spending reductions and enrollment losses across the states.
Innovate or Stagnate: Overcoming Model Governance Challenges in Life Sciences
By treating model governance as a proactive, integral part of operations rather than a box to check after the fact, life sciences organizations can uphold compliance, better allocate their resources, and gain a competitive edge. The post Innovate or Stagnate: Overcoming Model Governance Challenges in Life Sciences appeared first on MedCity News.
Workplace Violence Prevention in 2025
Workplace violence prevention is an ongoing and organic process. Federal and state regulations change frequently, so employers may consider regularly reviewing and updating their prevention plans and training programs on a scheduled timeline. The post Workplace Violence Prevention in 2025 appeared first on MedCity News.
